Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1:e000364.
Barrett CD, Dobos K, Liedtke M, et al. A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail. 2019;7:958-966.
Chakraborty R, Lentzsch S. Emerging drugs for the treatment of light chain amyloidosis. Expert Opin Emerg Drugs. 2020;25:299-317. \
ClinicalTrials.gov. A study of belantamab mafodotin in patients with relapsed or refractory AL amyloidosis (EMN27). NCT04617925. Updated March 3, 2021. Accessed April 22, 2021. https://www.clinicaltrials.gov/ct2/show/NCT04617925#:~:text=A%20Study%20of%20Belantamab%20Mafodotin%20in%20Patients%20With,the%20responsibility%20of%20the%20study%20sponsor%20and%20investigators.
ClinicalTrials.gov. A study to evaluate the effectiveness and safety of CAEL-101 in patients with Mayo stage IIIa AL amyloidosis. NCT04512235. Updated April 20, 2021. Accessed April 22, 2021. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2020-07136
Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.
Desport E, Bridoux F, Sirac C, et al. Al amyloidosis. Orphanet J Rare Dis. 2012;7:54.
Dispenzieri A. AL patients don't dare go without dara. Blood. 2020;135:1509-1510.
Dittrich T, Kimmich C, Hegenbart U, et al. Prognosis and staging of AL amyloidosis. Acta Haematol. 2020;143:388-399.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) [prescribing information]. Janssen Biotech, Inc. Approved 2020. Revised March 2021.
Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 2018;8:44.
Godara A, Zhou P, Rosenthal B, et al. B-Cell maturation antigen (BCMA) in systemic light-chain amyloidosis (AL): association with disease activity and its modulation with gamma-secretase inhibition. Blood. 2019;134 (suppl 1):4409.
Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38:3252-3260.
Kastritis E, Palladini G, Minnema MC, et al. Subcutaneous daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (CyborD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase 3 Andromeda study. Abstract LB2604. Presented at: EHA25 Virtual; June 14, 2020. Accessed April 22, 2021. https://library.ehaweb.org/eha/2020/eha25th/303396/efstathios.kastritis.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.html
Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900-902.
Lousada I, Comenzo RL, Landau Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32:920-928.
Maurer MS, Elliott P, Comenzo R. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135:1357-1377.
McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11:207-216.
Milani P, et al. Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood. 2018;132:1988-1991.
Muchtar E, Dispenzieri A, Kumar SK, et al. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016;101:1102-1109.
Muchtar E, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129: 2111-2119.
Narotsky DL, Castano A, Weinsaft JW, et al. Wild-type transthyretin cardiac amyloidosis: novel insights from advanced imaging. Can J Cardiol. 2016;32:1166.e1-1166.e10.
Palladini G, et al. Daratumumab in the treatment of light-chain (AL) amyloidosis. Cells. 2021;10:545.
Quarta CC, Kruger JL, Falk RH. Cardiac amyloidosis. Circulation. 2012;126:e178-182.
Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2:1046-1053
Sidiqi MH, et al. Daratumumab for the treatment of AL amyloidosis. Leuk Lymphoma. 2019;60:295-301.
Sidiqi MH, Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36:1323-1329.
Witteles RM, Liedtke M. AL Amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management. J Am Coll Cardiol CardioOnc. 2019;1:117-130.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Ray Comenzo, MD

Director, John C. Davis Myeloma & Amyloid Program
Professor, Tufts University School of Medicine in Boston, Massachusetts

Disclosures

Disclosure: Ray Comenzo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie/Genentech; Caelum/Alexion; Janssen; Karyopharm; Sanofi; Takeda
Received grants for clinical research from: Caelum/Alexion; Janssen
Other: Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies. Patent WO2016187546A1

Angela Dispenzieri, MD

Serene and Frances C. Durling Professor of Medicine and of Laboratory Medicine, and Pathology
Hematology Research Chair
Mayo Clinic
Rochester, Minnesota

Disclosures

Disclosure: Angela Dispenzieri, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alnylam; Intellia; Janssen
Received grants for clinical research from: Alnylan; Celgene; Janssen; Pfizer; Prothena; Takeda

Ronald Witteles, MD

Professor of Cardiovascular Medicine
Co-Director, Stanford Amyloid Center
Stanford University School of Medicine
Palo Alto, California

Disclosures

Disclosure: Ronald Witteles, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alnylam; Eidos; Ionis/Akcaea; Pfizer
Received grants for clinical research from: Alnylam; Eidos; Ionis/Akcaea; Pfizer

Editor

Cheryl Perkins, MD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Cheryl L Perkins, MD, RPh, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse planneri

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / ABIM MOC / CE

Expert Perspectives on AL Amyloidosis: Timely Identification for Improved Outcomes

Authors: Ray Comenzo, MD; Angela Dispenzieri, MD; Ronald Witteles, MD
CME / ABIM MOC / CE Released: 4/29/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/29/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, nephrologists, hematologists, primary care physicians, and nurses.

The goal of this activity is to educate clinicians about amyloid light chain (AL) amyloidosis characteristics and the importance of coordinating timely care with the interprofessional team.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- The clinical presentation of AL amyloidosis
- Data for emerging and new therapies for the treatment of AL amyloidosis
Have greater competence related to
- The diagnostic evaluation of patients who present with symptoms consistent with AL amyloidosis

Disclosures

Faculty

Ray Comenzo, MD

Director, John C. Davis Myeloma & Amyloid Program
Professor, Tufts University School of Medicine in Boston, Massachusetts

Disclosures

Disclosure: Ray Comenzo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie/Genentech; Caelum/Alexion; Janssen; Karyopharm; Sanofi; Takeda
Received grants for clinical research from: Caelum/Alexion; Janssen
Other: Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies. Patent WO2016187546A1

Angela Dispenzieri, MD

Serene and Frances C. Durling Professor of Medicine and of Laboratory Medicine, and Pathology
Hematology Research Chair
Mayo Clinic
Rochester, Minnesota

Disclosures

Disclosure: Angela Dispenzieri, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alnylam; Intellia; Janssen
Received grants for clinical research from: Alnylan; Celgene; Janssen; Pfizer; Prothena; Takeda

Ronald Witteles, MD

Professor of Cardiovascular Medicine
Co-Director, Stanford Amyloid Center
Stanford University School of Medicine
Palo Alto, California

Disclosures

Disclosure: Ronald Witteles, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alnylam; Eidos; Ionis/Akcaea; Pfizer
Received grants for clinical research from: Alnylam; Eidos; Ionis/Akcaea; Pfizer

Editor

Cheryl Perkins, MD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Cheryl L Perkins, MD, RPh, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse planneri

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Expert Perspectives on AL Amyloidosis: Timely Identification for Improved Outcomes

Authors: Ray Comenzo, MD; Angela Dispenzieri, MD; Ronald Witteles, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 4/29/2021

Valid for credit through: 4/29/2022, 11:59 PM EST

processing....

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

PDF Downloads

Downloadable PDF

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Ray Comenzo, MD

Angela Dispenzieri, MD

Ronald Witteles, MD

Editor

Cheryl Perkins, MD, RPh

CME, CE Reviewer / Nurse planneri

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

CME / ABIM MOC / CE

Expert Perspectives on AL Amyloidosis: Timely Identification for Improved Outcomes

Target Audience and Goal Statement

Disclosures

Faculty

Ray Comenzo, MD

Angela Dispenzieri, MD

Ronald Witteles, MD

Editor

Cheryl Perkins, MD, RPh

CME, CE Reviewer / Nurse planneri

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Expert Perspectives on AL Amyloidosis: Timely Identification for Improved Outcomes

PDF Downloads